PCSK9 inhibitors – past, present and future

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

(2015) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

A comparison of European and US guidelines for familial hypercholesterolaemia

(2015) Željko Reiner   CURRENT OPINION IN LIPIDOLOGY

Adverse Effects of Statins - Myths and Reality

(2015) Iveta Simic et al.   CURRENT PHARMACEUTICAL DESIGN

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Similarities and differences between European and United States guidelines for the management of dyslipidaemias

(2015) Željko Reiner   Kardiologia Polska

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

(2015) Michael J. Koren et al.   POSTGRADUATE MEDICINE

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011

(2014) K. K. Ray et al.   EUROPEAN HEART JOURNAL

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance and intolerance to statins

(2014) Ž. Reiner   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

(2013) Željko Reiner et al.   ATHEROSCLEROSIS

Prevalence and types of persistent dyslipidemia in patients treated with statins

(2013) Željko Reiner et al.   CROATIAN MEDICAL JOURNAL

Statins in the primary prevention of cardiovascular disease

(2013) Željko Reiner   Nature Reviews Cardiology

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL